Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma

There is a lack of prospective data about second-line treatments for metastatic pancreatic ductal adenocarcinoma patients. This is partially due to recent changes in first-line chemotherapy treatments. Despite this dearth of information, 50.0% of the patients who experience failure with first-line f...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncol Lett
Asıl Yazarlar: Sarabi, Matthieu, Mais, Laetitia, Oussaid, Nadia, Desseigne, Françoise, Guibert, Pierre, De La Fouchardiere, Christelle
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: D.A. Spandidos 2017
Konular:
Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5453056/
https://ncbi.nlm.nih.gov/pubmed/28599496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.6061
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller